Innate Pharma to Present P-II (MATISSE) Interim Data of IPH5201 in NSCLC at AACR 2026

Why It Matters

The early pCR signals suggest that targeting CD39 alongside PD‑L1 could improve surgical outcomes in NSCLC, a market where effective neoadjuvant immunotherapies are in high demand. Success could broaden Innate Pharma’s pipeline and accelerate adoption of novel checkpoint combinations.

Key Takeaways

• IPH5201 + durvalumab + chemo yields 35.7% pCR in PD‑L1 ≥1%
• pCR climbs to 50% in patients with PD‑L1 ≥50%
• Study enrolls 40 NSCLC patients; continues recruiting PD‑L1‑positive
• Dual CD39 and PD‑L1 blockade explored as perioperative strategy
• MATISSE Phase‑2 trial aims to expand anti‑CD39 immunotherapy

Pulse Analysis

The MATISSE Phase‑2 study marks one of the first clinical evaluations of CD39 inhibition in early‑stage lung cancer. CD39, an ectonucleotidase that generates immunosuppressive adenosine, has emerged as a complementary target to PD‑L1 because it modulates the tumor microenvironment upstream of T‑cell exhaustion. By pairing IPH5201 with durvalumab and standard chemotherapy, Innate Pharma aims to blunt both adenosine‑driven suppression and PD‑L1‑mediated checkpoint signaling, potentially converting more tumors to a state of complete pathological response before surgery.

Peri‑operative immunotherapy is gaining traction after trials like CheckMate‑816 demonstrated survival benefits from neoadjuvant checkpoint blockade. The interim pCR rates reported—35.7% for PD‑L1 ≥1% and 50% for PD‑L1 ≥50%—compare favorably with historical benchmarks for chemotherapy alone, suggesting that adding CD39 blockade may deepen responses in patients with higher PD‑L1 expression. These results also reinforce the hypothesis that dual inhibition can overcome resistance mechanisms that limit the efficacy of PD‑L1 monotherapy, especially in the immunologically “cold” microenvironments typical of early‑stage NSCLC.

For Innate Pharma, the data provide a strategic foothold in the competitive NSCLC neoadjuvant market and could unlock further regulatory incentives, such as accelerated approval pathways, if larger cohorts confirm the trend. Ongoing enrollment of PD‑L1‑positive patients will clarify the biomarker‑driven benefit and may support expansion into other solid tumors where CD39 is overexpressed. Investors and clinicians alike will watch the final MATISSE readout closely, as it could reshape combination immunotherapy paradigms and accelerate the adoption of anti‑CD39 agents across oncology.